Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress

Core Insights - Clearside Biomedical is showcasing its SCS Microinjector platform and CLS-AX program at the 25th EURETINA Congress, highlighting its potential for treating multiple retinal diseases [1][3] Group 1: SCS Microinjector Platform - The SCS delivery platform is designed for targeted treatment of retinal diseases such as wet AMD, diabetic retinopathy, and ocular cancer [2] - The SCS Microinjector allows for the delivery of various drug candidates into the suprachoroidal space, aiming to improve efficacy and reduce toxic effects on non-diseased cells [8][9] Group 2: CLS-AX Program - CLS-AX is a proprietary suspension of axitinib for suprachoroidal injection, which may offer advantages over existing retinal therapies by achieving pan-VEGF blockade [6][7] - The program includes a Phase 3 trial for wet AMD and a streamlined Phase 2 trial for non-proliferative diabetic retinopathy [3] Group 3: Upcoming Presentations - Dr. Sobha Sivaprasad will present Phase 2b results from the ODYSSEY trial and updates on the Phase 3 program for neovascular age-related macular degeneration [4] - Victor Chong will discuss the evolution of suprachoroidal drug delivery and participate in a panel at the Ophthalmology Futures Retina Forum [5]